Fxiii concentrate (human)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
288Autoimmune acquired coagulation factor deficiency [Autoimmune Hemorrhaphilia XIII (~Mar 2017)]3

288. Autoimmune acquired coagulation factor deficiency [Autoimmune Hemorrhaphilia XIII (~Mar 2017)]    [ 189 clinical trials,   219 drugs,   (DrugBank: 29 drugs),   18 drug target genes,   26 drug target pathways]
Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 189 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00945906
(ClinicalTrials.gov)
September 200923/7/2009An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyA Prospective, Multicenter, Open Enrollment Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyFactor XIII DeficiencyBiological: FXIII Concentrate (Human) (FXIII)CSL BehringNULLCompletedN/AN/AAll61Phase 3United States
2NCT00885742
(ClinicalTrials.gov)
August 200921/4/2009A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyA Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyFactor XIII DeficiencyBiological: FXIII Concentrate (Human)CSL BehringNULLCompletedN/AN/AAll41Phase 3United States;Spain
3NCT00883090
(ClinicalTrials.gov)
May 200916/4/2009A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII DeficiencyA 12 Week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyFactor XIII DeficiencyBiological: FXIII Concentrate (Human)CSL BehringNULLCompletedN/AN/AAll15Phase 2United States;Spain